These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 31010452)

  • 1. The role of dopamine D
    Calabrese F; Tarazi FI; Racagni G; Riva MA
    CNS Spectr; 2020 Jun; 25(3):343-351. PubMed ID: 31010452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Dopamine D
    Huang M; He W; Kiss B; Farkas B; Adham N; Meltzer HY
    J Pharmacol Exp Ther; 2019 Nov; 371(2):517-525. PubMed ID: 31511365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist.
    Citrome L
    Clin Schizophr Relat Psychoses; 2016; 10(2):109-19. PubMed ID: 27440212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine.
    Kiss B; Némethy Z; Fazekas K; Kurkó D; Gyertyán I; Sághy K; Laszlovszky I; Farkas B; Kirschner N; Bolf-Terjéki E; Balázs O; Lendvai B
    Drug Des Devel Ther; 2019; 13():3229-3248. PubMed ID: 31571826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of action of cariprazine.
    Stahl SM
    CNS Spectr; 2016 Apr; 21(2):123-7. PubMed ID: 26956157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO.
    Girgis RR; Slifstein M; D'Souza D; Lee Y; Periclou A; Ghahramani P; Laszlovszky I; Durgam S; Adham N; Nabulsi N; Huang Y; Carson RE; Kiss B; Kapás M; Abi-Dargham A; Rakhit A
    Psychopharmacology (Berl); 2016 Oct; 233(19-20):3503-12. PubMed ID: 27525990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mini Review on Cariprazine: A Promising Antipsychotic Agent.
    Patel A; Patel A; Patel D; Patel K; Bambharoliya T
    CNS Neurol Disord Drug Targets; 2023; 22(2):226-236. PubMed ID: 35331126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cariprazine:New dopamine biased agonist for neuropsychiatric disorders.
    De Deurwaerdère P
    Drugs Today (Barc); 2016 Feb; 52(2):97-110. PubMed ID: 27092339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cariprazine Exhibits Anxiolytic and Dopamine D3 Receptor-Dependent Antidepressant Effects in the Chronic Stress Model.
    Duric V; Banasr M; Franklin T; Lepack A; Adham N; Kiss B; Gyertyán I; Duman RS
    Int J Neuropsychopharmacol; 2017 Oct; 20(10):788-796. PubMed ID: 28531264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dopamine D₃-preferring D₂/D₃ dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia.
    Watson DJG; King MV; Gyertyán I; Kiss B; Adham N; Fone KCF
    Eur Neuropsychopharmacol; 2016 Feb; 26(2):208-224. PubMed ID: 26723167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression.
    Gründer G
    Curr Opin Investig Drugs; 2010 Jul; 11(7):823-32. PubMed ID: 20571978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.
    Kiss B; Horváth A; Némethy Z; Schmidt E; Laszlovszky I; Bugovics G; Fazekas K; Hornok K; Orosz S; Gyertyán I; Agai-Csongor E; Domány G; Tihanyi K; Adham N; Szombathelyi Z
    J Pharmacol Exp Ther; 2010 Apr; 333(1):328-40. PubMed ID: 20093397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cariprazine: A Review in Schizophrenia.
    Garnock-Jones KP
    CNS Drugs; 2017 Jun; 31(6):513-525. PubMed ID: 28560619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology.
    Neill JC; Grayson B; Kiss B; Gyertyán I; Ferguson P; Adham N
    Eur Neuropsychopharmacol; 2016 Jan; 26(1):3-14. PubMed ID: 26655189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents.
    Gyertyán I; Kiss B; Sághy K; Laszy J; Szabó G; Szabados T; Gémesi LI; Pásztor G; Zájer-Balázs M; Kapás M; Csongor EÁ; Domány G; Tihanyi K; Szombathelyi Z
    Neurochem Int; 2011 Nov; 59(6):925-35. PubMed ID: 21767587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia.
    Keks N; Hope J; Schwartz D; McLennan H; Copolov D; Meadows G
    CNS Drugs; 2020 May; 34(5):473-507. PubMed ID: 32246399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The dopamin D3 receptor--the gray eminence of pharmacotherapy?].
    Sumegi A; Varga E
    Neuropsychopharmacol Hung; 2010 Sep; 12(3):405-11. PubMed ID: 20962360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The novel atypical antipsychotic cariprazine demonstrates dopamine D
    Delcourte S; Ashby CR; Rovera R; Kiss B; Adham N; Farkas B; Haddjeri N
    CNS Neurosci Ther; 2018 Dec; 24(12):1129-1139. PubMed ID: 29729086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. D3 Receptor-Targeted Cariprazine: Insights from Lab to Bedside.
    Barabássy Á; Dombi ZB; Németh G
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cariprazine for the Treatment of Bipolar Disorder.
    Findlay LJ; El-Mallakh PL; El-Mallakh RS
    Perspect Psychiatr Care; 2017 Jul; 53(3):148-155. PubMed ID: 27059102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.